Respicardia, Inc. (formerly Cardiac Concepts, Inc.) is a privately held medical device company incorporated in 2006. It is located in Minneapolis, Minnesota, USA. It is developing an implantable system intended to improve the outcomes for Heart Failure patients by developing an implantable stimulation therapy to treat Central Sleep Apnea.
The remedē System is an implantable medical device that is being investigated in a clinical research study for the treatment of Central Sleep Apnea in patients with Heart Failure. It consists of three implantable components:
- remedē Pulse Generator comprised of electronic circuitry components and a battery, which are hermetically sealed in a titanium case
- remedē Stimulation Lead that is implanted in a vein close to one of the phrenic nerves
- a sensing lead to detect respiration
The remedē System also includes an external programmer used to change the pulse generator settings or to review diagnostic data via telemetry.
The remedē pulse generator delivers electrical pulses via a transvenous stimulation lead positioned within a vein close to one of the phrenic nerves. The phrenic nerve stimulation results in restoration of breathing to a more natural pattern. A more natural pattern of breathing may allow for better oxygenation, less activation of the sympathetic nervous system, and improved sleep.
The remedē System is designed to deliver electrical pulses at night during sleep to restore natural breathing.
Company website: www.cardiacconcepts.com
First US implant under IDE announced January 21, 2011.